Revenue
2024
OnKure Therapeutics, Inc. (OKUR)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — | — |
| Research & development | $48.3M | $43.8M | $32.1M | $37.7M | $28.2M | $15.9M |
| Operating expenses | $63.0M | $54.4M | $36.9M | $53.8M | $39.8M | $19.6M |
| Operating income | −$63.0M | −$54.4M | −$36.9M | −$53.8M | −$39.8M | −$19.6M |
| EBITDAderived | −$62.5M | −$53.9M | −$36.5M | −$53.8M | −$39.8M | −$19.5M |
| Net income | −$59.5M | −$52.7M | −$35.3M | −$52.0M | −$39.8M | −$19.5M |
| Basic EPSper diluted share | -$4.40 | -$15.28 | -$124.41 | -$2.12 | -$2.19 | -$9.60 |
| Diluted EPSper diluted share | -$4.40 | -$15.28 | -$124.41 | -$2.12 | -$2.19 | -$9.60 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 | Leverone Jason A.Chief Financial Officer | SellClass A Common Stock | 303 | $4.40 | $1.3K | 18.8K |
| Jun 22, 2026Form 4 | Saccomano Nicholas APresident and CEO | SellClass A Common Stock | 86 | $4.40 | $378.40 | 11.2K |
| Mar 23, 2026Form 4 | Leverone Jason A.Chief Financial Officer | SellClass A Common Stock | 301 | $4.16 | $1.3K | 16.0K |
| Mar 23, 2026Form 4 | Saccomano Nicholas APresident and CEO | SellClass A Common Stock | 86 | $4.16 | $357.76 | 7.3K |
| Dec 22, 2025Form 4 | Leverone Jason A.Chief Financial Officer | SellClass A Common Stock | 302 | $2.97 | $896.94 | 16.3K |